



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbara
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millonig
Lawrence B. Bugajsky
Donald J. Featherstone
Michael V. Messinger

Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Jeffrey T. Helvey
Heidi L. Kraus
Albert L. Ferro*
Donald R. Banowitz
Peter A. Jackman
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Eldora Ellison Floyd
Thomas C. Fiala
Brian J. Del Buono
Virgil Lee Beaston
Theodore A. Wood
Elizabeth J. Haanes

Joseph S. Ostroff
Frank R. Cottingham
Christine M. Lhulier
Rae Lynn P. Guest
George S. Bardmessner
Daniel A. Klein*
Jason D. Eisenberg
Michael D. Specht
Andrea J. Kamage
Tracy L. Muller*
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Aric W. Ledford*
Helene C. Carlson
Timothy A. Doyle*
Gaby L. Longsworth
Lori A. Gordon*

Nicole D. Dretar
Ted J. Ebersole
Jyoti C. Iyer*
Laura A. Vogel
Michael J. Mancuso
Registered Patent Agents*
Karen R. Markowicz
Nancy J. Leith
Matthew J. Dowd
Aaron L. Schwartz
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella
Jeffrey S. Lundgren
Victoria S. Rutherford
Michelle K. Holoubek

1684 (4) Dpw
Robert H. Delsims
Simon J. Elliott
Julie A. Heider
Mita Mukherjee
Scott M. Woodhouse
Michael G. Penn
Christopher J. Walsh

Of Counsel
Kenneth C. Bass III
Evan R. Smith
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
•Practice Limited to
Federal Agencies

December 9, 2004



Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

WRITER'S DIRECT NUMBER:
(202) 772-8619
INTERNET ADDRESS:
SCHWARTZ@SKGF.COM

Art Unit 1654

Re: U.S. Utility Patent Application
Application No. 09/937,484; 35 U.S.C. § 371 Date: January 23, 2002
For: **Use of a Lectin or Conjugates for Modulation of C-Fibre Activity**
Inventors: Foster *et al.*
Our Ref: 1581.0870000/RWE/ALS

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Credit Card Payment Form PTO-2038;
2. Fee Transmittal Form PTO/SB/17;
3. Second Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 (c);
4. Fifteen (15) pages of Form PTO-1449 citing fifty-nine (59) documents;
5. A copy of fifty-six (56) cited documents; and
6. One (1) return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
December 9, 2004
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.


Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Aaron L. Schwartz
Agent for Applicants
Registration No. 48,181

ALS/law
Enclosures
342516v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL

for FY 2005

Effective 10/01/2004. Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 180.00)

Complete if Known

Application Number	09/937,484
Filing Date	§ 371 Date: January 23, 2002
First Named Inventor	Keith Alan Foster
Examiner Name	Audet, Maury A.
Art Unit	1654
Attorney Docket No.	1581.0870000/RWE/ALS

METHOD OF PAYMENT (check all that apply)

Check Credit card Money Order Other None

**Charge any deficiencies or credit any overpayments in

 Deposit Account: the fees to Deposit Acct. No. 19-0036.

Deposit Account Number 19-0036
Deposit Account Name Sterne, Kessler, Goldstein & Fox P.L.L.C.

The Director is authorized to: (check all that apply)

Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) or any underpayment of fee(s)
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1001 790	2001 395			Utility filing fee	
1002 350	2002 175			Design filing fee	
1003 550	2003 275			Plant filing fee	
1004 790	2004 395			Reissue filing fee	
1005 160	2005 80			Provisional filing fee	
SUBTOTAL (1) (\$)		-0-			

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Independent Claims	Multiple Dependent	Extra Claims	Fee from below	Fee Paid
			-20*	=	
			+ 3**	=	
				=	

Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	Fee Description
1202 18	2202 9			Claims in excess of 20
1201 88	2201 44			Independent claims in excess of 3
1203 300	2203 150			Multiple dependent claim, if not paid
1204 88	2204 44			** Reissue independent claims over original patent
1205 18	2205 9			** Reissue claims in excess of 20 and over original patent
SUBTOTAL (2) (\$)		-0-		

**or number previously paid, if greater; For Reissues, see above

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code (\$)	Fee (\$)	Fee Code (\$)	Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	430	2252	215	Extension for reply within second month	
1253	980	2253	490	Extension for reply within third month	
1254	1,530	2254	765	Extension for reply within fourth month	
1255	2,080	2255	1,040	Extension for reply within fifth month	
1401	340	2401	170	Notice of Appeal	
1402	340	2402	170	Filing a brief in support of an appeal	
1403	300	2403	150	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,370	2453	685	Petition to revive - unintentional	
1501	1,370	2501	685	Utility issue fee (or reissue)	
1502	490	2502	245	Design issue fee	
1503	660	2503	330	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	790	2809	395	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	790	2810	395	For each additional invention to be examined (37 CFR 1.129(b))	
1801	790	2801	395	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	
Other fee (specify)		-			
*Reduced by Basic Filing Fee Paid		SUBTOTAL (3) (\$)		180.00	

(Complete if applicable)

Name (Print/Type)	Aaron L. Schwartz	Registration No. (Attorney/Agent)	48,181	Telephone	(202) 371-2600
Signature		Date	December 9, 2004		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Confirmation No.: 2134

Foster *et al.*

Art Unit: 1654

Appl. No.: 09/937,484

Examiner: Audet, Maury A.

35 U.S.C. §371 date: January 23, 2002

Atty. Docket: 1581.0870000/RWE/ALS

For: **Use of a Lectin or Conjugates for
Modulation of C-Fibre Activity**

**Second Supplemental Information Disclosure Statement
under 37 C.F.R. § 1.97(c)**

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed on April 18, 2002 in connection with the above-captioned application. Copies of the documents are submitted herewith.

Further to the recent notice "Changes To Support Implementation of the United States Patent and Trademark Office 21st Century Strategic Plan; Final Rule," copies of all of the U.S. patents or published patent applications cited on the accompanying PTO-1449 forms need not be provided. 1287 O.G. 67 (October 12, 2004); 69 Fed. Reg. 56481 (September 21, 2004).

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language documents **AO2** and **AT14** cited on Form PTO 1449:

Document **AO2** is in a foreign language. An unverified English language abstract of document **AO2** is provided herewith as document **AR14**;

Document **AT14** is in a foreign language. An unverified English language abstract of document **AT14** appears on page 2 of the same document.

The Examiner's attention is directed document **AL4** which is the published PCT application from which co-pending U.S. patent application 09/529,130 to Duggan *et al.* (35 U.S.C. § 371 date: June 22, 2000) is derived. This U.S. patent application is directed to related technical subject matter. The identification of this U.S. patent application is not to be construed as a waiver of secrecy as to this application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination. The substantive examination details and Applicants' replies are also provided herewith as documents **AR16 - AT21**. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to this application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is

not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. Attached is our PTO-2038 Credit Card Payment Form in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Aaron L. Schwartz
Agent for Applicants
Registration No. 48,181

Date: December 9, 2004

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

334847_1.DOC

FORM PTO-1449

DEC 8 9 2004

SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1581.0870000/RWE/ALSAPPLICATION NO.
09/937,484FIRST NAMED INVENTOR
*Foster et al.*35 U.S.C. §371 Date:
January 23, 2002ART UNIT
1654

TRADEMARKS, PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB1	5,989,545	11/23/1999	<i>Foster et al.</i>			01/12/1998
AC1	5,668,255	09/16/1997	Murphy			08/04/1993
AD1	5,721,207	02/24/1998	<i>Noble et al.</i>			04/18/1995
AE1						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP1	WO 94/28923	12/22/1994	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR			
AS	7		Adar, R., et. al., "The amino acid sequence of <i>Erythrina corallodendron</i> lectin and its homology with other legume lectins," <i>FEBS Lett.</i> 257:81-85, Elsevier Science B.V. (1989)
AT	7		Arora, N., et. al., "Cytotoxic Effects of a Chimeric Protein Consisting of Tetanus Toxin Light Chain and Anthrax Toxin Lethal Factor in Non-neuronal Cells," <i>J. Biol. Chem.</i> 269:26165-26171, American Society for Biochemistry and Molecular Biology (1994)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET NO. 1581.0870000/RWE/ALS	APPLICATION NO. 09/937,484
			FIRST NAMED INVENTOR <i>Foster et al.</i>	35 U.S.C. §371 Date: January 23, 2002
			ART UNIT 1654	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL2	WO 95/32738	12/07/1995	WIPO			Yes No
	AM2	WO 97/18790	05/29/1997	WIPO			Yes No
	AN2	WO 98/07864	02/26/1998	WIPO			Yes No
	AO2	DE 197 35 105 A1	03/04/1999	Germany			Abstract Yes No
	AP2	WO 91/09871	07/11/1999	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	8	Brinkmann, U., et. al., "A recombinant immunotoxin containing a disulfide-stabilized Fv fragment," <i>Proc. Natl. Acad. Sci. USA</i> 90:7538-7542, Abstract No. 8356052, National Academy of Sciences (1993)
AS	8	Kurazono, H., et. al., "Minimal Essential Domains Specifying Toxicity of the Light Chains of Tetanus Toxin and Botulinum Neurotoxin Type A," <i>J. Biol. Chem.</i> 267:14721-14729, The American Society for Biochemistry and Molecular Biology, Inc. (1992)
AT	8	Lamb, F. I., et. al., "Nucleotide sequence of cloned cDNA coding for preproricin," <i>Eur. J. Biochem.</i> 148:265-270, Blackwell Science Ltd. on behalf of the Federation of European Biochemical Societies, (1985)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 1581.0870000/RWE/ALS	APPLICATION NO. 09/937,484
		FIRST NAMED INVENTOR Foster <i>et al.</i>	35 U.S.C. §371 Date: January 23, 2002
		ART UNIT 1654	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL3	WO 92/15327	09/17/1992	WIPO			Yes No
AM3	WO 93/04191	03/04/1993	WIPO			Yes No
AN3	WO 93/15766	08/19/1993	WIPO			Yes No
AO3	WO 96/12802	05/02/1996	WIPO			Yes No
AP3	WO 98/08540	03/05/1998	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	9	Law, I. J., "Cloning and expression of cDNA for galactose-binding lectin from peanut nodules," <i>Plant Science</i> 115:71-79, Elsevier Science Ireland Ltd. (1996)
AS	9	Lorberboum-Galski, H., <i>et. al.</i> , "Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 85:1922-1926, National Academy of Sciences (1988)
AT	9	Murphy, J.R., "Diphtheria-related peptide hormone gene fusions: a molecular genetic approach to chimeric toxin development," <i>Cancer Treat. Res.</i> 37:123-140, Kluwer Academic (1988)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</u>			ATTY. DOCKET NO. 1581.087000/RWE/ALS	APPLICATION NO. 09/937,484
			FIRST NAMED INVENTOR Foster <i>et al.</i>	35 U.S.C. §371 Date: January 23, 2002

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL4	WO 99/17806	4/15/1999	WIPO			Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>10</u>	"NeuroBloc (Botulinum Toxin Type B) For Cervical Dystonia Launched in UK," <i>Doctor's Guide</i> , P/S/L Consulting Group Inc. (March 2001), visited November 28, 2001 at < http://www.psigroup.com/dg/1F4216.htm >
AS	<u>10</u>	O'Hare, M., <i>et. al.</i> , "Cytotoxicity of a recombinant ricin-A-chain fusion protein containing a proteolytically-cleavable spacer sequence," <i>FEBS Lett.</i> 273:200-204. Elsevier Science B.V. (1990)
AT	<u>10</u>	Plank, C., <i>et. al.</i> , "The Influence of Endosome-disruptive Peptides on Gene Transfer Using Synthetic Virus-like Gene Transfer Systems," <i>J. Biol. Chem.</i> 269:12918-12924, American Society for Biochemistry and Molecular Biology (1994)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449			ATTY. DOCKET NO. 1581.087000/RWE/ALS	APPLICATION NO. 09/937,484
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT			FIRST NAMED INVENTOR Foster <i>et al.</i>	
			35 U.S.C. §371 Date: January 23, 2002	ART UNIT 1654

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	11	Van Damme, E.J., <i>et. al.</i> , "Molecular cloning of the bark and seed lectins from the Japanese pagoda tree (<i>Sophora japonica</i>)," <i>Plant Molec. Biol.</i> 33:523-536, Kluwer Academic Publishers (1997)
AS	11	Williams, D.P., <i>et. al.</i> , "Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein," <i>Protein Eng.</i> 1:493-498, Oxford University Press (1987)
AT	11	Wood, K.A., <i>et. al.</i> , "Preproabrin: genomic cloning, characterisation and the expression of the A-chain in <i>Escherichia coli</i> ," <i>Eur. J. Biochem.</i> 198:723-732, Blackwell Science Ltd. on behalf of the Federation of European Biochemical Societies, (1991)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET NO. 1581.0870000/RWE/ALS	APPLICATION NO. 09/937,484
			FIRST NAMED INVENTOR <i>Foster et al.</i>	35 U.S.C. §371 Date: January 23, 2002

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>12</u>	Yamaguchi, O., et. al., "Chemical Structures of Two Subunits, A-Subunit and B-Subunit, of Galactose-Specific Isolectins from <i>Erythrina variegata</i> Seeds," <i>J. Biochem. (Tokyo)</i> 114:560-566, Oxford University Press for Japanese Biochemical Society (1993)
AS	<u>12</u>	Black, J.D., and Dolly, J.O., "Interaction of ¹²⁵ I-Labeled Botulinum Neurotoxins with Nerve Terminals. I. Ultrastructural Autoradiographic Localization and Quantitation of Distinct Membrane Acceptors for Types A and B on Motor Nerves," <i>J. Cell Biol.</i> 103:521-534, The Rockefeller University Press (1986)
AT	<u>12</u>	Blaustein, R.O., et. al., "The N-terminal half of the heavy chain of botulinum type A neurotoxin forms channels in planar phospholipid bilayers," <i>FEBS Letts.</i> 226:115-120, Elsevier Science Publishers B.V. (1987)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET NO. 1581.0870000/RWE/ALS		APPLICATION NO. 09/937,484		
			FIRST NAMED INVENTOR Foster <i>et al.</i> 35 U.S.C. §371 Date: January 23, 2002		ART UNIT 1654		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	AR	<u>13</u>	Shone, C.C., <i>et. al.</i> , "Inactivation of <i>Clostridium botulinum</i> type A neurotoxin by trypsin and purification of two tryptic fragments: Proteolytic action near the COOH-terminus of the heavy subunit destroys toxin-binding activity," <i>Eur. J. Biochem.</i> 151:75-82, Springer International (1985)				
	AS	<u>13</u>	Sutton, J.M., <i>et. al.</i> , "Tyrosine-1290 of tetanus neurotoxin plays a key role in its binding to gangliosides and functional binding to neurones," <i>FEBS Letts.</i> 493:45-49, Elsevier Science B.V. (March 2001)				
	AT	<u>13</u>	Yamazaki, N., <i>et. al.</i> , "Endogenous lectins as targets for drug delivery," <i>Advanced Drug Delivery Reviews</i> 43:225-244, Elsevier Science B.V. (September 2000)				
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET NO. 1581.0870000/RWE/ALS		APPLICATION NO. 09/937,484	
			FIRST NAMED INVENTOR Foster <i>et al.</i>		35 U.S.C. §371 Date: January 23, 2002	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	14	Dialog File 351, WPI Accession no. 1999-168079/199915, Derwent WPI English language abstract for DE 197 35 105 (Document AO2)
AS	14	Welch, M.J., <i>et. al.</i> , "Sensitivity of embryonic rat dorsal root ganglia neurons to <i>Clostridium botulinum</i> neurotoxins," <i>Toxicon</i> 38:245-258, Pergamon Press (February 2000)
AT	14	Besson, J.M., "La complexité des aspects physiopharmacologiques de la douleur," <i>Drugs</i> 53:1-9, ADIS Press (1997)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 1581.0870000/RWE/ALS		APPLICATION NO. 09/937,484	
		FIRST NAMED INVENTOR Foster <i>et al.</i>		35 U.S.C. §371 Date: January 23, 2002	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL					Yes No
	AM					Yes No
	AN					Yes No
	AO					Yes No
	AP					Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>15</u>	Sharon, N., and Lis, H., "Legume lectins-a large family of homologous proteins," <i>The FASEB J.</i> 4:3198-3208, The Federation of American Societies for Experimental Biology (1990)
AS	<u>15</u>	Zambenedetti, P., <i>et. al.</i> , "Identification of lectin binding sites in the rat brain," <i>Glycoconjugate J.</i> 13:341-346, Chapman & Hall (1996)
AT	<u>15</u>	Lis, H., and Sharon, N., "Lectins as Molecules and as Tools," <i>Ann. Rev. Biochem.</i> 55:35-67, Annual Reviews, Inc. (1986)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 <u>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 1581.087000/RWE/ALS	APPLICATION NO. 09/937,484
		FIRST NAMED INVENTOR <i>Foster et al.</i>	
		35 U.S.C. §371 Date: January 23, 2002	ART UNIT 1654

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>16</u>	Kam, C.-M., Office Communication for the United States Patent Application No. 09/529,130, 8 pages, United States Patent and Trademark Office (mailed on March 1, 2001)
AS	<u>16</u>	Esmond, R.W., filing for United States Patent Application No. 09/529,130, 3 pages, "Reply to Restriction Requirement" (filed April 3, 2001)
AT	<u>16</u>	Kam, C.-M., Office Communication for United States Patent Application No. 09/529,130, 15 pages, United States Patent and Trademark Office (mailed August 14, 2001)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 1581.0870000/RWE/ALS		APPLICATION NO. 09/937,484	
		FIRST NAMED INVENTOR Foster <i>et al.</i>		35 U.S.C. §371 Date: January 23, 2002	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL					Yes No
	AM					Yes No
	AN					Yes No
	AO					Yes No
	AP					Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	17	Esmond, R.W., filing for the United States Patent Application No. 09/529,130, 51 pages, "Preliminary Amendment and Reply Under 37 C.F.R. §1.111" (filed December 14, 2001)
AS	17	Kam, C.-M., Office Communication for United States Patent Application No. 09/529,130, 20 pages, United States Patent and Trademark Office (mailed March 19, 2002)
AT	17	Chalker, B.E., filing for United States Patent Application No. 09/529,130, 43 pages, "Amendment and Reply Under 37 C.F.R. § 1.111" (filed September 10, 2002)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 1581.0870000/RWE/ALS	APPLICATION NO. 09/937,484
		FIRST NAMED INVENTOR <i>Foster et al.</i>	35 U.S.C. §371 Date: January 23, 2002

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>18</u>	Kam, C.-M., Office Communication for United States Patent Application No. 09/529,130, 11 pages, United States Patent and Trademark Office (mailed November 26, 2002)
AS	<u>18</u>	Chalker, B.E., filing for United States Patent Application No. 09/529,130, 14 pages, "Amendment And Reply Under 37 C.F.R. § 1.111" (filed April 25, 2003)
AT	<u>18</u>	Kam, C.-M., Office Communication for United States Patent Application No. 09/529,130, 8 pages, United States Patent and Trademark Office (mailed July 7, 2003)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 1581.087000/RWE/ALS		APPLICATION NO. 09/937,484	
		FIRST NAMED INVENTOR Foster et al.		35 U.S.C. §371 Date: January 23, 2002	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>19</u>	Schwartz, A.L., filing for United States Patent Application No. 09/529,130, 19 pages, "Amendment and Reply Under 37 C.F.R. § 1.116" (filed September 25, 2003)
AS	<u>19</u>	Kam, C.-M., Office Communication for United States Patent Application No. 09/529,130, 3 pages, United States Patent and Trademark Office (mailed October 23, 2003)
AT	<u>19</u>	Schwartz, A.L., filing for United States Patent Application No. 09/529,130, 7 pages, "Preliminary Amendment and Reply" (filed November 7, 2003)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET NO. 1581.0870000/RWE/ALS	APPLICATION NO. 09/937,484
			FIRST NAMED INVENTOR <i>Foster et al.</i>	35 U.S.C. §371 Date: January 23, 2002

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL					Yes No
	AM					Yes No
	AN					Yes No
	AO					Yes No
	AP					Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	20	Kam, C.-M., Office Communication for United States Patent Application No. 09/529,130, 13 pages, United States Patent and Trademark Office (mailed January 28, 2004)
AS	20	Esmond, R.W., filing for United States Patent Application No. 09/529,130, 7 pages, "Amendment and Reply Under 37 C.F.R. § 1.111" (filed April 28, 2004)
AT	20	Kam, C.-M., Office Communication for United States Patent Application No. 09/529,130, 15 pages, United States Patent and Trademark Office (mailed July 9, 2004)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET NO. 1581.0870000/RWE/ALS	APPLICATION NO. 09/937,484
			FIRST NAMED INVENTOR <i>Foster et al.</i>	35 U.S.C. §371 Date: January 23, 2002
			ART UNIT 1654	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	21	Schwartz, A. L., filing for United States Patent Application No. 09/529,130, 10 pages, "Amendment and Reply Under 37 C.F.R. § 1.111" (filed December 9, 2004)
	AS	21	Chaddock, J., Declaration Under 37 C.F.R. § 1.132 for U.S. Application No. 09/529,130, (filed December 9, 2004)
	AT	21	Foster, K., Declaration Under 37 C.F.R. § 1.132 for U.S. Application No. 09/529,130, (filed December 9, 2004)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.